Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - ENZON PHARMACEUTICALS, INC. | Financial_Report.xls |
| EX-32.1 - EXHIBIT 32.1 - ENZON PHARMACEUTICALS, INC. | v324822_ex32-1.htm |
| EX-10.5 - EXHIBIT 10.5 - ENZON PHARMACEUTICALS, INC. | v324822_ex10-5.htm |
| EX-10.1 - EXHIBIT 10.1 - ENZON PHARMACEUTICALS, INC. | v324822_ex10-1.htm |
| EX-31.1 - EXHIBIT 31.1 - ENZON PHARMACEUTICALS, INC. | v324822_ex31-1.htm |
| EX-32.2 - EXHIBIT 32.2 - ENZON PHARMACEUTICALS, INC. | v324822_ex32-2.htm |
| EX-10.4 - EXHIBIT 10.4 - ENZON PHARMACEUTICALS, INC. | v324822_ex10-4.htm |
| EX-10.2 - EXHIBIT 10.2 - ENZON PHARMACEUTICALS, INC. | v324822_ex10-2.htm |
| EX-31.2 - EXHIBIT 31.2 - ENZON PHARMACEUTICALS, INC. | v324822_ex31-2.htm |
| EX-10.6 - EXHIBIT 10.6 - ENZON PHARMACEUTICALS, INC. | v324822_ex10-6.htm |
| 10-Q - FORM 10-Q - ENZON PHARMACEUTICALS, INC. | v324822_10q.htm |
Exhibit 10.3
AMENDMENT NO. 2
AMENDMENT TO
LICENSE AND COLLABORATION AGREEMENT
THIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 25th day of June 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
BACKGROUND
WHEREAS, Enzon and Santaris entered into the License and Collaboration Agreement dated July 26, 2006 (the “Agreement”); and
WHEREAS, Enzon and Santaris desire to amend and restate certain provisions of the Agreement.
NOW, THEREFORE, in consideration of the covenants and obligations expressed herein and intending to be legally bound, and otherwise bound by proper and reasonable conduct, the Parties agree as follows:
1. Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the Agreement.
2. The table in Section 6.1(a) of the Agreement is hereby amended and restated in its entirety as follows:
|
Development Milestone |
Time to Achieve |
|
Determination to: (i) select an Accepted LNA Compound for Development (i.e., designation of a Selected LNA Compound) and (ii) commence pre-clinical toxicology study therefor (other than for SPC2968 or SPC3042) |
18 months after delivery (or such longer period of time as extended pursuant to Section 5.5) by Santaris of the Accepted LNA Compound |
|
Filing of an IND in the Enzon Territory for the first Product for each Enzon Target |
(a) December 31, 2006 in respect of SPC2968;
(b) 24 months after the Effective Date in respect of SPC3042; and
(c) in respect of other Selected LNA Compounds, 18 months after designation by Enzon as a Selected LNA Compound against each Additional Target |
3. Except as set forth in this Amendment, the Agreement shall remain in full force and effect.
4. Resolution of all disputes arising out of or related to this Amendment or the performance, enforcement, breach or termination of this Amendment and any remedies relating thereto, shall be governed by and construed under the substantive Laws of the State of New York, without regard to conflicts of law rules that would provide for application of the Law of a jurisdiction outside New York. To the extent there is any such dispute, such dispute will be handled in accordance with the procedures set forth in Section 13 of the Agreement.
| 1 |
5. This Amendment may be executed in two or more counterparts (including by facsimile or .pdf file) each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
[Remainder of Page Intentionally Left Blank]
| 2 |
IN WITNESS WHEREOF, the Parties have executed this Amendment in duplicate originals by their proper officers as of the date and year first above written.
| SANTARIS PHARMA A/S | ENZON PHARMACEUTICALS, INC. |
| By: /s/Keith McCullagh | By: /s/Ivan Horak |
| NAME: Keith McCullagh | NAME: Ivan Horak |
| TITLE: CEO | TITLE: EVP – R&D, CSO |
| By: /s/Henrik Stage | |
| NAME: Henrik Stage | |
| TITLE: CFO |
| 3 |